Jemperli global net sales rose 34% year-over-year to $644 million. The company reported positive interim results for the AZUR-1 pivotal trial and anticipates a 2027 FDA decision on expansion to rectal cancer.
Jemperli global net sales rose 34% year-over-year to $644 million. The company reported positive interim results for the AZUR-1 pivotal trial and anticipates a 2027 FDA decision on expansion to rectal cancer.